EFFECT OF PHASE VOLUME RATIO OVER POLYMER DRUG RATIO IN THE PREPARATION OF GEFITINIB LOADED-POLY-E-CAPROLACTONE MICROCAPSULE

Susovita Khuntia, Priyangi Roy

Abstract


The study was to design to formulate, evaluate and optimize the gefitinib-loaded poly-e-caprolactone microcapsules controlled release delivery system. It may be used as a potential alternate to conventional drug delivery system found to have serious limitations/drawbacks. The microcapsules were prepared by the solvent evaporation technique. Effects of different polymer: drug ratios and phase volume ratios (Independent variables) on the % drug entrapment efficiency, % Yield and mean particle sizes (Response variables) with the overall desirability characteristics were studied through 32 full Factorial design. The results showed the % drug entrapment efficiency: 46.58±0.085-84.39±0.500%, % Yield: 37.14±0.083-64.23±0.652%, and mean particle sizes: 47.42±1.241-115.37±0.44μ. Highest overall desirability was obtained from the optimized formulation comprising at 0.0 level of polymer: drug ratio and 1.0 level of phase volume ratio and it was selected for the further evaluation. Scanning electron microscopy image of microcapsules was discrete and spherical. Fourier transform Infrared Spectroscopy and Differential scanning electometry spectral analysis revealed the absence of drug-polymer interaction. The formulation showed burst release of 5.93% upto 1 h followed by sustained release of 23.89% upto 276 h. Drug release kinetics was fitted with Zero order, First order and Higuchi Model. Best fitted Higuchi’s model assured the potential controlled gefitinib release form the microcapsules. This preliminary study indicated the gefitinib loaded- poly-e-caprolactone microcapsules could be the potential drug delivery system for continuous controlled release for prolongs time. However, this study could be substantiated by the performance of in vivo.

EFFECT OF PHASE VOLUME RATIO OVER POLYMER DRUG RATIO IN THE PREPARATION OF GEFITINIB LOADED-POLY-E-CAPROLACTONE MICROCAPSULE


Keywords


gefitinib, poly-e-caprolactone, microcapsules, optimize, desirability, controlled release

Full Text:

Full Text in pdf

References


AstraZeneca, 2013: Gefitinib, available at https://www.cancercare.on.ca/cms/One.aspx? portalId=1377&pageId=10760, accessed on 06th October 18, 2013.

Mishra, B., Biswal, P. K., Sahoo, J., Dixit, P. K., (2016): Formulation, evaluation and in-vitro release study of diltiazem hcl loaded gelatinous microspher, Biopharm J., 2(1), p.27-33.

Bruce, A.C., Jeffrey, B., Joel, N.L, Erin, O., Hamza, M., Lecia, S, et al., (2011): Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokine. In: Laurence LB, editor.Goodman & Gillman’s the Pharmacological Basis of Therapeutics, New York, McGraw-Hill, p.1731-54.

Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., et al. (2000): Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6(5), p.053-63.

Cohen, M. H., William, G.A., Sridhara, R., Chen, G., Pazdur, R., (2003): FDA Drug approval summary: Gefitinib (ZD 1839) (Iressa(R) tablets. Oncologist, 8, p.303-06.

Cochran, W.G., Cox, G.M., (1992) Experimental design. 2nd Ed, John Wiley & Sons, New York, p.335-75.

Corrigan, O.I., Xue, L., (2009): Quantifying drug release from PLGA nanoparticulates. Euro. J. Pharm. Sci., 37 (3–4), p.477–85.

Costa, P., Lobo, J. M. S., (2001): Modeling and comparison of dissolution profiles. Euro. J. Pharm. Sci., 13(2), p.123–33.

David, M. K., Elizabeth, A.P, John, V.K., Mike, P.S., Jane, K., Sharon, B., et al. (2005): Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther. 4(4), 641-49.

Dobaria, N.B., Badhan, A.C., Mashru, R.C., (2009): A Novel Itraconazole Bioadhesive Film for Vaginal Delivery: Design,Optimization, and Physicodynamic Characterization. AAPS Pharm. Sci. Tech., 10(3), p.951-59.

DrugBank, Gefitinib, available at https://www.drugbank.ca/ drugs/ DB00317, accessed on 6th October 6, 2013.

DrugBank, Iressa Dosage, available at https://www.drugs.com/dosage/iressa.html, accessed on 06 th October 16, 2013.

Dunne M, Corrigan O, Ramtoola Z. (2000): Influence of particle size and dissolution condition on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 21, p.1659–68.

Edlund, U., Albertson, A.C., (2002): Degradable Polymer Microspheres for Controlled Drug Delivery, In Advances in Polymer Science, Springer-Verlag Berlin Heidelberg, 2002; p.157:67-112.

Ferlay, J., Shin, H.R., Bray F., Forman, D, Mathers, C, Parkin, DM et al., (2010) . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127(12), p.2893-17.

Li, J., Kleeff, J., Giese, N., Büchler, M.W., Korc, M., Friess, H., (2004): Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol., 25(1), p.203-10.

Ming, L., Olivier, R., Denis, P., (2008): Microencapsulation by solvent evaporation: State of the art for process engineering approaches. Int. J. Phar., 363: p.26–39.

Myer, K. (2003): Standard Handbook of Biomedical Engineering & Design, McGraw-Hill Companies Inc.

Robert, L.M., Richard, F.G., James, L., (2003): Statistical Design and Analysis of Experiments: With Application to Engineering and Scienc, .2nd Ed, John Wiley and Sons, New Jersy, p.69-658.

Nils, O. G., Monica, J., Timo, L., (2006): Cores and microcapsules suitable for parenteral administration as well as process for their manufacture, Canadian Patents, CA 2609891 A1, available at http://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2609891/summary.html, accessed on, 28th October, 2016.

Redhead, H.M., Davis, S.S., Illum, L., (2001): Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterization and in vivo evaluation. J. Control Rel. 70, p.353–63.

Roy, P., Gartia, P., Nayek, A., Samanta, A.K., (2012): Preparation of gefitinib loaded-poly-e-caprolactone microcapsule for controlled release drug delivery system. Int. J. Pharmacol. Pharm. Tech., 1 (2), p.57-61.

Siegel-Lakhai, W.S., Beijnena, J.H., Schellens, J.H.M., (2005): Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (TarcevaR) and Gefitinib(IressaR).The Oncologist, 10, p.579-89.

Sinha, V.R., Bansal, K., Kaushik, R., Kumri, R., Trehan, A. (2004): Poly-e-caprolactone microsphere and nanospheres: an overview. Int. J Pharm, 278:1–23.

Santander-Ortega, M. J., Jódar-Reyes, A.B., Csaba, N., Bastos-González, D., Ortega-Vinuesa, J.L., (2006): Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilization mechanisms. J Colloid and Interface Sci. 302, p. 522–29.

Woodruff, M.A., Hutmacher, D.W. (2010): The return of forgotten polymer: Polycaprolactone in the 21st century, Progr. Poly. Sci., 35(10), p.1217-1256.

Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, et al. (2006): Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Research, 4 (12), p.971-981.


Refbacks

  • There are currently no refbacks.




Copyright © 2015 BIOPHARM JOURNAL  - ISSN 2454-1397 & Powered by Sona Nfinity